175 hasil untuk "Gandy, Sam"
Menampilkan 1–20 · 0,19 detik · RSS
-
Artikel Jurnal Teks lengkap
Alzheimer's Disease: New Data Highlight Nonneuronal Cell Types and the Necessity for Presymptomatic Prevention Strategies
Despite compelling genetic evidence indicating that cerebral amyloidosis can be, at least sometimes, the primary cause of Alzheimer's disease (AD), clinical trials for symptomatic AD with amyloid-reducing agents have succeeded at target engagement but failed to cause clinical benefit. In a landmark…
-
Artikel Jurnal Teks lengkap
Prevention is better than cure
Attempts to reduce amyloid-β in the brain have yet to show clinical benefits. Starting treatment early is the best hope, says Sam Gandy.
-
Artikel Jurnal Teks lengkap
The role of cerebral amyloid β accumulation in common forms of Alzheimer disease
For approximately 80 years following Alzheimer’s description of the disease that bears his name, a gulf divided researchers who believed that extracellular deposits of the amyloid β (Aβ) peptide were pathogenic from those who believed that the deposits were secondary detritus. Since 1990, the…
-
Artikel Jurnal Teks lengkap
Lifelong Management of Amyloid-Beta Metabolism to Prevent Alzheimer’s Disease
-
Artikel Jurnal Teks lengkap
News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer’s disease in 2023
-
Artikel Jurnal Teks lengkap
Evidence that an APOE ε4 'double whammy' increases risk for Alzheimer's disease
Abstract Temporal lobe epilepsy (TLE) is associated with some of the same neuropathological features as those reported for early stages of typical Alzheimer's disease (AD). The APOE ε4 allele is associated with a gene-dose-dependent increase in AD risk and in the severity of amyloid-β (Aβ)…
Juga tersedia di: PubMed Central
-
Artikel Jurnal Teks lengkap
New pathway links γ-secretase to inflammation and memory while sparing Notch
-
Artikel Jurnal Teks lengkap
Solanezumab—prospects for meaningful interventions in AD?
A treatment trial of the monoclonal anti-amyloid antibody solanezumab showed slight benefits in people with dementia due to mild Alzheimer disease. Drug effects on several neuropsychological testing outcomes were statistically significant, but the effect sizes were unlikely to manifest as…
-
Artikel Jurnal Teks lengkap
The Golgi apparatus: Site for convergence of COVID-19 brain fog and Alzheimer’s disease?
-
Artikel Jurnal Teks lengkap
Amyloid-β Oligomers: Possible Roles as Key Neurotoxins in Alzheimer’s Disease
Alzheimer’s disease is the most common form of senile dementia. Although the amyloid-β peptide was identified in 1984 as the major constituent of the senile plaques that characterize the disease, accumulating evidence indicates that the plaque density does not correspond well to the concurrent…
-
Artikel Jurnal Teks lengkap
Latrepirdine (Dimebon(®)), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model
Alzheimer disease (AD) is a form of neurodegeneration that develops over the course of multiple decades and as a result of the accumulation of the pathogenic amyloid-β (Aβ) peptide, also known as A4. In late-stage AD, failure of autophagic clearance results in neuronal cell bodies that are almost…
-
Artikel Jurnal Teks lengkap
Toward the Treatment and Prevention of Alzheimer’s Disease: Rational Strategies and Recent Progress
Alzheimer’s disease (AD) is the major cause of late-life brain failure. In the past 25 years, autosomal dominant forms of AD were found to be primariy attributable to mutations in one of two presenilins, polytopic proteins that contain the catalytic site of the γ-secretase protease that releases…
-
Artikel Jurnal Teks lengkap
Breaking Up (Amyloid) Is Hard to Do
Gandy and Heppner discuss the implications of a new animal study on our understanding of the pathogenesis and treatment of Alzheimer disease.